Article Data

  • Views 691
  • Dowloads 136

Original Research

Open Access

Thrombus prevalence and risk factors in critically ill pediatric patients

  • Aylin Akti1,*,
  • Ozden Ozgur Horoz2
  • Dincer Yildizdas2
  • Merve Misirlioglu2
  • Faruk Ekinci2
  • Goksel Leblebisatan3
  • Sevcan Tug Bozdogan4

1Department of Pediatrics, Cukurova University Faculty of Medicine, 01330 Adana, Türkiye

2Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, 01330 Adana, Türkiye

3Department of Pediatric Hematology, Cukurova University Faculty of Medicine, 01330 Adana, Türkiye

4Department of Medical Genetics, Cukurova University Faculty of Medicine, 01330 Adana, Türkiye

DOI: 10.22514/sv.2024.143 Vol.20,Issue 11,November 2024 pp.49-55

Submitted: 03 March 2024 Accepted: 06 June 2024

Published: 08 November 2024

*Corresponding Author(s): Aylin Akti E-mail: aktitugrul@gmail.com

Abstract

We aimed to ascertain the prevalence of venous and arterial thrombus, potential thrombosis-inducing factors, and underlying medical conditions in critically ill pediatric patients admitted to our pediatric intensive care unit. We included patients who were admitted to our tertiary pediatric intensive care unit for 24 hours between June 2016 and June 2021 and had venous or arterial thrombosis confirmed by Doppler ultrasonography. Thirty patients with confirmed thrombosis who underwent Doppler ultrasonography and thirty patients without thrombosis, matched based on age and gender, were included in the control group. The female gender accounted for 63.3% of the patients in the thrombosis group. There was no significant gender difference between the thrombosis group and the control group. Age (in months), height, weight, and body mass index measurements were similar in both groups. The most common reason for hospitalization in the thrombosis group was post-operative care (n = 7; 23.3%). Thrombosis typically occurred after a mean of 6.9 ± 4.9 days of hospitalization. Coagulation parameters, Protein C, Protein S, homocysteine levels, pediatric mortality index (PIM), pediatric risk of mortality (PRISM-2), and Braden Q scores evaluating pressure ulcersdid not differ significantly between the two groups. Eleven patients in the thrombosis group were screened for the prothrombin 20210A mutation, with all results being normal; eleven patients in the patient group were tested for Factor V Leiden mutation, and nine patients in the control group had no mutation. The thrombosis group had a significantly lower rate of mechanical ventilation and hemodialysis. Factors such as trauma, infection, heart failure, malignancy, history of chemotherapy, immobilization, presence of central catheter, history of surgical intervention, family history, and nephrotic syndrome were not significantly associated with thrombosis development. Central venous and arterial catheterization was identified as the most crucial acquired risk factor for thrombosis.


Keywords

Arterial; Pediatric intensive care; Thrombosis; Venous


Cite and Share

Aylin Akti,Ozden Ozgur Horoz,Dincer Yildizdas,Merve Misirlioglu,Faruk Ekinci,Goksel Leblebisatan,Sevcan Tug Bozdogan. Thrombus prevalence and risk factors in critically ill pediatric patients. Signa Vitae. 2024. 20(11);49-55.

References

[1] van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. The Journal of Pediatrics. 2001; 139: 676–681.

[2] O’Brien SH, Stanek JR, Witmer CM, Raffini L. The continued rise of venous thromboembolism a cross US children’s hospitals. Pediatrics. 2022; 149: e2021054649.

[3] Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009; 124: 1001–1008.

[4] Andrew M, Marzinotto V, Pencharz P, Zlotkin S, Burrows P, Ingram J, et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. The Journal of Pediatrics. 1995; 126: 358–363.

[5] Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. The Journal of Pediatrics. 1998; 133: 770–776.

[6] Teja B, Bosch NA, Diep C, Pereira TV, Mauricio P, Sklar MC, et al. Complication rates of central venous catheters: a systematic review and meta-analysis. JAMA Internal Medicine. 2024; 184: 474–482.

[7] Braun BI, Kolbusz KM, Bozikis MR, Schmaltz SP, Abe K, Reyes NL, et al. Venous thromboembolism performance measurement in the United States: an evolving landscape with many stakeholders. To be published in Journal of Hospital Medicine. 2024. [Preprint].

[8] Stevens SM, Woller SC, Baumann Kreuziger L, Doerschug K, Geersing GJ, Klok FA, et al. Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012–2021. To be published in Chest. 2024. [Preprint].

[9] Sochet AA, Jaffray J, Branchford BR, Havlicek EE, Mosha M, Amankwah EK, et al. Hospital-acquired venous thromboembolism and invasive mechanical ventilation: a report from the children’s hospital acquired thrombosis consortium. Pediatric Critical Care Medicine. 2024; 25: e82–e90.

[10] Lin TL, Liu WH, Lai WH, Chen YJ, Chang PH, Chen IL, et al. The incidence and risk factors of proximal lower extremity deep vein thrombosis without pharmacologic prophylaxis in critically ill surgical Taiwanese patients: a prospective study. Journal of the Intensive Care Society. 2023; 25:140–146.

[11] Sandoval JA, Sheehan MP, Stonerock CE, Shafique S, Rescorla FJ, Dalsing MC. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk. Journal of Vascular Surgery. 2008; 47: 837–843.

[12] DeAngelis GA, McIlhenny J, Willson DF, Vittone S, Dwyer SJ 3rd, Gibson JC, et al. Prevalence of deep venous thrombosis in the lower extremities of children in the intensive care unit. Pediatric Radiology. 1996; 26: 821–824.

[13] Stančiaková L, Othman M, Kubisz P. Management of venous and arterial thrombosis. Journal of Clinical Medicine. 2024; 13: 2744.

[14] Gonzalez AB, Mulet YM, Song N, Loh L, Scheinker D, Shin AY, et al. Predictive ability of the Braden QD scale for hospital-acquired venous thromboembolism in hospitalized children. The Joint Commission Journal on Quality and Patient Safety. 2022; 48: 513–520.

[15] Higgerson RA, Lawson KA, Christie LM, Brown AM, McArthur JA, Totapally BR, et al; National Association of Childrenʼs Hospitals and Related Institutionʼs Pediatric Intensive Care Unit FOCUS group. Incidence and risk factors associated with venous thrombotic events in pediatric intensive care unit patients. Pediatric Critical Care Medicine. 2011; 12: 628–634.

[16] Stokes S, Breheny P, Radulescu A, Radulescu VC. Impact of obesity on the risk of venous thromboembolism in an inpatient pediatric population. Journal of Pediatric Hematology/Oncology. 2014; 31: 475–480.

[17] Torres-Ramirez RJ, Escalera C, Cushner FD, Long WJ, Rodriguez JA. The use of aspirin for venous thromboembolism prophylaxis in patients who have morbid obesity undergoing primary and revision total joint arthroplasty. To be published in The Journal of Arthroplasty. 2024. [Preprint].

[18] Raptopoulou A, Michou V, Mourtzi N, Papageorgiou EG, Voyiatzaki C, Tsilivakos V, et al. Large-scale screening for factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek population. Health Science Reports. 2022; 5: e457.

[19] Jaffray J, Mahajerin A, Branchford B, Nguyen ATH, Faustino EVS, Silvey M, et al. A new risk assessment model for hospital-acquired venous thromboembolism in critically ill children: a report from the children’s hospital-acquired thrombosis consortium. Pediatric Critical Care Medicine. 2022; 23: e1–e9.

[20] Branchford BR, Betensky M, Goldenberg NA. Pediatric issues in thrombosis and hemostasis: the how and why of venous thromboembolism risk stratification in hospitalized children. Thrombosis Research. 2018; 172: 190–193.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.3 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top